Questions Remain With CAR-T’s, Checkpoints in Hematologic Malignancies – OncLive
OncLive |
Questions Remain With CAR–T's, Checkpoints in Hematologic Malignancies
OncLive Despite major progress with chimeric antigen receptor (CAR) T-cell therapy and immune checkpoint inhibitors in hematologic malignancies, questions remain regarding the use of these therapies in this landscape, according to Leo I. Gordon, MD. |
